Greater understanding of polycystic ovary syndrome
29 September 2015A new genetic study of over 200,000 women reveals the underlying mechanisms of polycystic ovary syndrome, as well as potential interventions.
A new genetic study of over 200,000 women reveals the underlying mechanisms of polycystic ovary syndrome, as well as potential interventions.
Graham Ladds, lecturer in pharmacology, discusses the controversy around a group of drugs used to treat Type 2 diabetes.
Scientists have found that some drugs from a group of anti-diabetic treatments may, in certain circumstances, act on glucagon receptors in the body, meaning that they could also potentially enable the release of sugar into the bloodstream.
The Cambridge Animal Alphabet series celebrates Cambridge's connections with animals through literature, art, science and society. Here, N is for Naked Mole-Rats, which won't win any beauty contests, but can live for 30 years and may be able to help in the development of new therapies for chronic pain.
If it takes more than three trips to the GP to be referred for cancer tests, patients are more likely to be dissatisfied with their overall care, eroding confidence in the doctors and nurses who go on to treat and monitor them, according to new research.
A protein that targets the effects of a faulty gene could offer the first treatment targeting the major genetic cause of pulmonary arterial hypertension, according to research funded by the British Heart Foundation (BHF) and carried out at the University of Cambridge.
Human stem cell research holds promise for combating some of the most recalcitrant of diseases and for regenerating damaged bodies. It is also an ethical, legal and political minefield.
Researchers believe the gene could be a useful therapeutic target for treating obesity and type 2 diabetes
Approval concludes nearly 40-year epic journey from fundamental research to discovery of an effective treatment for active relapsing multiple sclerosis
Phone therapy also increases access and potentially decreases costs.